购物车
全部删除
您的购物车当前为空
PARP/EZH2-IN-2 (compound 12e) 是一种针对PARP1和EZH2的双重抑制剂,IC50分别为6.89和27.34 nM。该化合物展现抗癌活性,对正常细胞无毒性。通过抑制EZH2来提高对PARP1的敏感性,PARP/EZH2-IN-2 间接实现合成致死,并通过调控过度自噬诱导细胞死亡。
PARP/EZH2-IN-2 (compound 12e) 是一种针对PARP1和EZH2的双重抑制剂,IC50分别为6.89和27.34 nM。该化合物展现抗癌活性,对正常细胞无毒性。通过抑制EZH2来提高对PARP1的敏感性,PARP/EZH2-IN-2 间接实现合成致死,并通过调控过度自噬诱导细胞死亡。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 待询 | |
| 50 mg | 待询 | 待询 |
PARP/EZH2-IN-2 相关产品
| 产品描述 | PARP/EZH2-IN-2 (compound 12e) functions as a dual inhibitor targeting both PARP1 and EZH2, with IC50 values of 6.89 and 27.34 nM, respectively. This compound exhibits anticancer activity without toxicity to normal cells, achieving synthetic lethality indirectly by increasing PARP1 sensitivity through EZH2 inhibition, and inducing cell death by modulating excessive autophagy. |
| 靶点活性 | EZH2:27.34 ± 1 nM, PARP1:6.89 ± 0.7 nM |
| 体外活性 | PARP/EZH2-IN-2 (compound 12e) 对 MDA-MB-231 细胞(IC 50 = 2.84 μM)和 BT-549 细胞(IC 50 = 0.91 μM)表现出最强的细胞毒性,但对正常乳腺细胞系无毒性。 |
| 体内活性 | PARP/EZH2-IN-2 (compound 12e) (20-50 mg/kg, 腹腔注射) 展现出卓越的抗肿瘤活性,优于 Niraparib+ GSK126。 |
| 分子式 | C33H31N7O3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容